BR0008674A - Método para tratar ou prevenir a proliferação de fibroblastos dentro do olho, tratar ou prevenir a neovascularização de tecidos oculares, acelerar a clarificação do sangue hemorrágico do humor vìtreo, causar a dissolução não-enzimática da interface hialóide e/ou causar a separação ou a desinserção do vìtreo posterior - Google Patents
Método para tratar ou prevenir a proliferação de fibroblastos dentro do olho, tratar ou prevenir a neovascularização de tecidos oculares, acelerar a clarificação do sangue hemorrágico do humor vìtreo, causar a dissolução não-enzimática da interface hialóide e/ou causar a separação ou a desinserção do vìtreo posteriorInfo
- Publication number
- BR0008674A BR0008674A BR0008674-6A BR0008674A BR0008674A BR 0008674 A BR0008674 A BR 0008674A BR 0008674 A BR0008674 A BR 0008674A BR 0008674 A BR0008674 A BR 0008674A
- Authority
- BR
- Brazil
- Prior art keywords
- treat
- prevent
- eye
- disinsertion
- vitreous
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Abstract
"MéTODO PARA TRATAR OU PREVENIR A PROLIFERAçãO DE FIBROBLASTOS DENTRO DO OLHO, TRATAR OU PREVENIR A NEOVASCULARIZAçãO DE TECIDOS OCULARES, ACELERAR A CLARIFICAçãO DO SANGUE HEMORRáGICO DO HUMOR VìTREO, CAUSAR A DISSOLUçãO NãO-ENZIMáTICA DA INTERFACE HIALóIDE E/OU CAUSAR A SEPARAçãO OU A DESINSERçãO DO VìTREO POSTERIOR". Métodos e preparações para tratamento de distúrbios do olho e/ou causadores de desinserção ou separação do vítreo posterior. Preparações contendo a) uréia, b) derivados de uréia (por exemplo, hidróxi-uréia, tiouréia), c) agentes antiinflamatórios não-esteroidais, d) antimetabólitos, e) uréia, derivados de uréia, proteínas não-enzimáticas, nucleosídeos, nucleotídeos e seus derivados (por exemplo, adenina, adenosina, citosina, citadina, guanina, guanitadina, guanidínio, timidina, timitadina, uradina, uracila, cistina), ácido úrico, acetal-salicilato de cálcio, sulfato de amónio ou outro composto capaz de causar dissolução não-enzimática da membrana hialóide ou e) quaisquer das possíveis combinações dos mesmos, são administradas ao olho em quantidades terapeuticamente efetivas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12250399P | 1999-03-02 | 1999-03-02 | |
PCT/US2000/005587 WO2000051620A1 (en) | 1999-03-02 | 2000-03-02 | Agents for intravitreal administration to treat or prevent disorders of the eye |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0008674A true BR0008674A (pt) | 2002-02-13 |
Family
ID=22403079
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0008674-6A BR0008674A (pt) | 1999-03-02 | 2000-03-02 | Método para tratar ou prevenir a proliferação de fibroblastos dentro do olho, tratar ou prevenir a neovascularização de tecidos oculares, acelerar a clarificação do sangue hemorrágico do humor vìtreo, causar a dissolução não-enzimática da interface hialóide e/ou causar a separação ou a desinserção do vìtreo posterior |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1165095B1 (pt) |
JP (2) | JP2002538125A (pt) |
KR (1) | KR20010108296A (pt) |
CN (2) | CN1377272A (pt) |
AT (1) | ATE396734T1 (pt) |
AU (2) | AU780299B2 (pt) |
BG (1) | BG105867A (pt) |
BR (1) | BR0008674A (pt) |
CA (1) | CA2366050C (pt) |
DE (1) | DE60039043D1 (pt) |
ES (1) | ES2307498T3 (pt) |
IL (2) | IL145226A0 (pt) |
MX (1) | MXPA01008729A (pt) |
NZ (1) | NZ513836A (pt) |
RU (1) | RU2286157C2 (pt) |
WO (1) | WO2000051620A1 (pt) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030199574A1 (en) | 2000-03-02 | 2003-10-23 | Vitreo-Retinal Technologies, Inc. | Treatment of ophthalmic disorders using urea and urea derivatives |
US7977385B2 (en) | 2000-03-02 | 2011-07-12 | Numoda Biotechnologies, Inc. | Agents for corneal or intrastromal administration to treat or prevent disorders of the eye |
WO2003007798A2 (en) * | 2001-07-20 | 2003-01-30 | Iomed, Inc. | Ophthalmic use of 5 fluorourcil |
WO2003007961A1 (en) * | 2001-07-20 | 2003-01-30 | Iomed, Inc. | Methods for treating neoplastic, angiogenic, fibroplastic, and/or immunosuppresive ocular irregularities via administration of methotrexate based medicaments, and ocular iontophoretic devices for delivering methotrexate based medicaments |
WO2003068166A2 (en) * | 2002-02-13 | 2003-08-21 | Vitreo-Retinal Technologies, Inc. | Treatment of ophthalmic disorders using urea and urea derivatives |
JP2005522464A (ja) * | 2002-03-14 | 2005-07-28 | ビトレオ−レチナール テクノロジーズ インコーポレイテッド | 眼の障害の治療または予防のために角膜または実質内に投与する薬剤 |
MXJL02000046A (es) * | 2002-12-13 | 2004-06-24 | Jimenez Bayardo Arturo | Solucion inyectable intravitrea para el tratamiento de hemorragias vitreas. |
CN101385697B (zh) * | 2008-10-30 | 2012-10-03 | 中国科学院上海药物研究所 | 氟比洛芬酯眼用纳米乳-原位凝胶制剂及其制备方法 |
RU2497498C2 (ru) * | 2012-02-14 | 2013-11-10 | Константин Николаевич Руссков | Фармацевтическая композиция для профилактики пролиферативной клеточной реакции "митомицин-о" |
AU2013201465B2 (en) * | 2012-10-24 | 2016-03-03 | Rayner Surgical (Ireland) Limited | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
CN103393631B (zh) * | 2013-08-22 | 2015-04-08 | 北京蓝丹医药科技有限公司 | 一种氟比洛芬酯药物组合物 |
WO2015138391A1 (en) * | 2014-03-11 | 2015-09-17 | Rhee Douglas J | Methods of treating glaucoma using amp-activated protein kinase (ampk) activators |
TWI705812B (zh) | 2014-12-01 | 2020-10-01 | 奥默羅斯公司 | 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液 |
WO2017021560A1 (fr) * | 2015-08-06 | 2017-02-09 | Centre Hospitalier National D'ophtalmologie Quinze-Vingts | Utilisation d'hydroxycarbamide pour prevenir la non-perfusion retinienne |
AU2017231765A1 (en) | 2016-03-10 | 2018-08-23 | Oxurion NV | Posterior ocular fibrosis inhibition by antagonizing placental growth factor |
EP3500312B1 (en) * | 2016-08-18 | 2024-04-10 | Troy Bremer | Delivery of urea to cells of the macula and retina using liposome constructs |
WO2018208826A1 (en) * | 2017-05-08 | 2018-11-15 | Meharry Medical College | Hydroxyurea to enhance sperm cells |
GB2573784B (en) * | 2018-05-17 | 2020-10-07 | Nova Bio Pharma Product Dev Ltd | A stable aqueous hydroxycarbamide solution |
CN108721327A (zh) * | 2018-08-24 | 2018-11-02 | 苏州药明康德新药开发股份有限公司 | 实验动物视网膜色素变性试验模型的制备方法 |
CA3129429A1 (en) * | 2019-02-08 | 2020-08-13 | Ohio State Innovation Foundation | Antioxidant-releasing vitreous substitutes and uses thereof |
JP2022146830A (ja) * | 2021-03-22 | 2022-10-05 | 均 石井 | 網膜剥離治療薬。 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU604236B2 (en) * | 1986-04-28 | 1990-12-13 | Iolab, Inc. | Intraocular dosage compositions and method of use |
US5110493A (en) * | 1987-09-11 | 1992-05-05 | Syntex (U.S.A.) Inc. | Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant |
HU199072B (en) * | 1987-09-11 | 1990-01-29 | Syntex Inc | Antimicrobal conserving composition and process for production of compositions for oculist purpuses |
US5470881A (en) * | 1993-09-09 | 1995-11-28 | West Virginia University Research Corporation | Urea ophthalmic ointment and solution |
US5441984A (en) * | 1994-01-06 | 1995-08-15 | Eli Lilly And Company | Urea, thiourea and guanidine derivatives |
AU3609795A (en) * | 1994-10-10 | 1996-05-02 | Novartis Ag | Ophthalmic and aural compositions containing diclofenac potassium |
US5891084A (en) * | 1994-12-27 | 1999-04-06 | Lee; Vincent W. | Multiple chamber catheter delivery system |
US5554187A (en) * | 1995-08-18 | 1996-09-10 | Rizzo, Iii; Joseph | Medication dispensing intra-ocular lens system |
-
2000
- 2000-03-02 EP EP00916034A patent/EP1165095B1/en not_active Expired - Lifetime
- 2000-03-02 AT AT00916034T patent/ATE396734T1/de not_active IP Right Cessation
- 2000-03-02 IL IL14522600A patent/IL145226A0/xx active IP Right Grant
- 2000-03-02 ES ES00916034T patent/ES2307498T3/es not_active Expired - Lifetime
- 2000-03-02 CN CN00807107A patent/CN1377272A/zh active Pending
- 2000-03-02 KR KR1020017011153A patent/KR20010108296A/ko not_active Application Discontinuation
- 2000-03-02 NZ NZ513836A patent/NZ513836A/xx not_active IP Right Cessation
- 2000-03-02 WO PCT/US2000/005587 patent/WO2000051620A1/en active IP Right Grant
- 2000-03-02 RU RU2001124272/14A patent/RU2286157C2/ru active
- 2000-03-02 CN CN200910222821A patent/CN101711737A/zh active Pending
- 2000-03-02 DE DE60039043T patent/DE60039043D1/de not_active Expired - Fee Related
- 2000-03-02 JP JP2000602088A patent/JP2002538125A/ja active Pending
- 2000-03-02 CA CA2366050A patent/CA2366050C/en not_active Expired - Lifetime
- 2000-03-02 BR BR0008674-6A patent/BR0008674A/pt not_active Application Discontinuation
- 2000-03-02 MX MXPA01008729A patent/MXPA01008729A/es active IP Right Grant
- 2000-03-02 AU AU37201/00A patent/AU780299B2/en not_active Expired
-
2001
- 2001-09-01 BG BG105867A patent/BG105867A/xx unknown
- 2001-09-02 IL IL145226A patent/IL145226A/en not_active IP Right Cessation
-
2005
- 2005-06-14 AU AU2005202579A patent/AU2005202579A1/en not_active Abandoned
-
2010
- 2010-12-03 JP JP2010270694A patent/JP5428101B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CA2366050C (en) | 2011-05-24 |
CN101711737A (zh) | 2010-05-26 |
IL145226A (en) | 2007-07-04 |
CN1377272A (zh) | 2002-10-30 |
EP1165095A4 (en) | 2004-12-15 |
EP1165095B1 (en) | 2008-05-28 |
RU2286157C2 (ru) | 2006-10-27 |
CA2366050A1 (en) | 2000-09-08 |
KR20010108296A (ko) | 2001-12-07 |
DE60039043D1 (de) | 2008-07-10 |
AU780299B2 (en) | 2005-03-17 |
IL145226A0 (en) | 2002-06-30 |
ATE396734T1 (de) | 2008-06-15 |
WO2000051620A1 (en) | 2000-09-08 |
AU3720100A (en) | 2000-09-21 |
EP1165095A1 (en) | 2002-01-02 |
BG105867A (en) | 2002-04-30 |
JP5428101B2 (ja) | 2014-02-26 |
AU2005202579A1 (en) | 2005-07-07 |
JP2002538125A (ja) | 2002-11-12 |
NZ513836A (en) | 2004-01-30 |
JP2011088911A (ja) | 2011-05-06 |
ES2307498T3 (es) | 2008-12-01 |
MXPA01008729A (es) | 2003-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0008674A (pt) | Método para tratar ou prevenir a proliferação de fibroblastos dentro do olho, tratar ou prevenir a neovascularização de tecidos oculares, acelerar a clarificação do sangue hemorrágico do humor vìtreo, causar a dissolução não-enzimática da interface hialóide e/ou causar a separação ou a desinserção do vìtreo posterior | |
Karnofsky et al. | Cellular effects of anticancer drugs | |
Balzarini et al. | Potent and selective anti-HTLV-IIILAV activity of 2′, 3′-dideoxycytidinene, the 2′, 3′-unsaturated derivative of 2′, 3′-dideoxycytidine | |
De Clercq | Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development | |
DK172617B1 (da) | Ny medicinsk anvendelse af nukleosider | |
BR9914097A (pt) | Composto, uso do mesmo, composição farmacêutica e método de profilaxia ou tratamento de uma infecção viral e processo para preparação do composto | |
Cronstein | The antirheumatic agents sulphasalazine and methotrexate share an anti-inflammatory mechanism | |
BR0314236A (pt) | Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos | |
Hartmann et al. | Enhanced in vitro inhibition of HIV-1 replication by 3′-fluoro-3′-deoxythymidine compared to several other nucleoside analogs | |
MY103760A (en) | Therapeutic nucleosides | |
BR9800228A (pt) | Compostos de peridilfurano e piridiltiofeno | |
US7109181B2 (en) | Joint lubrication with P2Y purinergic receptor agonists | |
WO1997035591B1 (en) | Method of treating ciliary dyskinesia with uridine triphosphates and related compounds | |
RU2001124272A (ru) | Средства для введения в стекловидное тело для лечения или предотвращения заболеваний глаз | |
JP7311855B2 (ja) | 嗜癖および関連する障害を処置するための化合物および方法 | |
US5686428A (en) | Pharmaceutical composition | |
EP1074258A3 (en) | Methods and compositions for treating diseases and conditions of the eye | |
BR0308403A (pt) | Método para tratamento de um distúrbio do olho de um paciente humano ou veterinário, e, uso de um composto | |
MONTEFIORI et al. | In vitro evaluation of mismatched double-stranded RNA (ampligen) for combination therapy in the treatment of acquired immunodeficiency syndrome | |
Baba et al. | Synergistic antiviral effects of antiherpes compounds and human leukocyte interferon on varicella-zoster virus in vitro | |
EP0286825A3 (en) | Use of 3'-fluro-3' deoxythymidine for the manufacture of a medicament for the treatment of virus infections | |
US5670520A (en) | Method for inhibiting virus replication in mammalian cells using carbostyil derivatives | |
DE50212933D1 (de) | Die verwendung von pyrimidinnukleosiden und/oder prodrugs davon zur bekämpfung von nebenwirkungen der "haart" (highly active anti-retroviral therapy) und anderen antiviralen therapien | |
JPH02142733A (ja) | ジドブジン含有エイズ治療剤 | |
FRIEDMAN et al. | Seizures in a patient receiving terbutaline |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S)10(VIII) DA LPI |
|
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |